Munich - Delayed Quote EUR

Eli Lilly and Co (LLY.MU)

640.40

-17.60

(-2.67%)

As of 8:00:58 AM GMT+2. Market Open.

Did Eli Lilly Just Say Checkmate to Novo Nordisk?

A clinical trial showed that Lilly's weight loss medicine is superior to a key competitor's product. Eli Lilly (NYSE: LLY) is one of the undisputed leaders in developing anti-obesity medicines, with Novo Nordisk (NYSE: NVO) being its biggest challenger. Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it.

Motley Fool 50 minutes ago

LLY

NVO
Wegovy and Zepbound costs capped at $200 in new Evernorth programme

The lower out-of-pocket costs come at a time of governmental scrutiny on prescription drug prices in the US.

Pharmaceutical Technology 53 minutes ago

CI

NVO

GLDAF
Lilly’s Kisunla marketing for Alzheimer’s authorised in Australia

The decision to register the therapy was supported by data from the Phase III TRAILBLAZER-ALZ 2 and TRAILBLAZER-ALZ 6 trials.

Pharmaceutical Technology 1 hour ago

LLY
Lilly's Kisunla (donanemab) receives marketing authorization in Australia for the treatment of early symptomatic Alzheimer's disease

Eli Lilly and Company (NYSE: LLY) announced today that the Australian Therapeutic Goods Administration (TGA) has granted marketing authorization for Kisunla (donanemab), an injection for intravenous infusion every four weeks to treat mild cognitive impairment and mild dementia due to Alzheimer's disease in adults who are Apolipoprotein E ε4 (ApoE ε4) heterozygotes or non-carriers. Kisunla is the first amyloid-targeting therapy for people with Alzheimer's registered in Australia and the only amyl

PR Newswire 16 hours ago

LLY
Lilly’s former small molecule head makes the leap to a rising biotech in obesity

Utpal Singh joined the peptide-focused biotech Zealand Pharma last month after it notched a massive obesity deal with Roche.

Pharma Voice yesterday

ROG.SW

LLY
Novo Nordisk Places Bet on CEO Shake-Up to Reclaim Edge in Weight Loss Drug Race

As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing medicine, Zepbound, the Danish pharmaceutical behemoth Novo Nordisk A/S (NYSE:NVO) abruptly announced the resignation of veteran CEO Lars Fruergaard Jørgensenm last week. The stock has dropped by over 49% in the past year, wiping out over […]

Insider Monkey yesterday

NVO

LLY
Novo Nordisk Shares Dip 3% on Sudden CEO Transition Announcement

NVO stock declines 3% as the company announces that Lars Fruergaard Jorgensen will be stepping down as the CEO.

Zacks 2 days ago

NVO

LLY
Novo Nordisk (NVO) Slides After CEO Departure; Analyst Flags Deeper Strategic Concerns

Shares fall nearly 4% as BMO warns leadership change won't fix core issues

GuruFocus.com 3 days ago

NVO

LLY
3 Stocks Estimated To Be Trading Up To 49.2% Below Intrinsic Value

The United States market has experienced a positive trend, climbing 2.9% in the last week and showing a 12% increase over the past year, with earnings projected to grow by 14% annually. In this environment, identifying stocks that are trading below their intrinsic value can present opportunities for investors seeking to capitalize on potential growth while maintaining a focus on fundamental value.

Simply Wall St. 3 days ago

LLY

KD

STZ
Novo Nordisk’s CEO to step down as weight loss market share plummets

Novo Nordisk stated that replacing Jørgensen is "in the best interests of the company and its shareholders".

Pharmaceutical Technology 3 days ago

LLY

NVO
Judge shuts down drugmakers’ 340B rebate plans, for now

A district court ruled that the HHS does have the power to review drug manufacturers’ plans to pay hospitals rebates instead of upfront discounts on 340B medications. But it left the door open to the controversial reforms.

Healthcare Dive 3 days ago

SNY

CELG-RT

NVS
Eli Lilly and Co (LLY): Expands Genetic Hearing Loss Pipeline with $1.3B RNA Therapy Partnership

On May 16, Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA-based gene therapies for sensorineural hearing loss, with milestone payments exceeding $1.3 billion. Rznomics will lead early-stage research, while Lilly handles clinical development and commercialization using RNA editing, a reversible alternative to CRISPR. The collaboration complements Lilly’s existing genetic hearing […]

Insider Monkey 4 days ago

LLY
Trump administration not backing down on Big Pharma pressure campaign

The pharmaceutical industry's patience is wearing thin with the Trump administration's pressure. But the administration doesn't care.

Yahoo Finance 4 days ago

LLY

RHHBF

RHHBY
Analysis-Novo Nordisk should look to the US for its next CEO, analysts say

(Reuters) -As Denmark's Novo Nordisk shops for its next CEO to replace Lars Fruergaard Jorgensen, it should look across the Atlantic for a leader deeply entrenched in the United States, by far its largest market, analysts told Reuters. Novo, which manufactures the popular weight-loss drug Wegovy, said on Friday its current CEO will step down over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market. Financial analysts Reuters spoke with said an American may be better placed to deal with a Trump administration, which is rewriting the rules on pharmaceutical trade, manufacturing, regulation and drug pricing.

Reuters 5 days ago

NVO

LLY
From insulin to Ozempic, history of Novo Nordisk's CEOs

Jorgensen, who joined in 2017, has had the shortest tenure of all. Danish couple August and Marie Krogh founded Nordsik Insulinlaboratorium in 1923 and commercialized the production of insulin. The company competed with Novo Terapeutisk Laboratorium, which was founded by brothers Harald and Thorvald Pedersen, until the two merged in 1989.

Reuters 5 days ago

NVO

LLY
Eli Lilly strikes $1.3bn gene therapy deal with Rznomics

The deal gives Lilly access to the company’s RNA-editing platform to develop therapies for sensorineural hearing loss.

Pharmaceutical Technology 5 days ago

LLY
Galaxy Digital on the Nasdaq, Novo ousts CEO, Virgin Galactic

Yahoo Finance host Josh Lipton tracks today's top moving stocks and biggest market stories in this Market Minute, including Galaxy Digital's (GLXY) debut on the Nasdaq, Eli Lilly (LLY) getting a lift after Novo Nordisk (NVO) pushed out its CEO Lars Fruergaard Jørgensen, and Virgin Galactic (SPCE) forecasting passenger space flights in the fall of 2026. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.

Yahoo Finance Video 5 days ago

GLXY

LLY

SPCE
Novo Nordisk Sheds 3% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price

Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition.

Investor's Business Daily 5 days ago

VKTX

LLY

AMGN
Novo Nordisk Boots CEO After Stock Falls 50%. It’s an Unusual Move for the Wegovy Drugmaker.

It was a ‘mutual agreement,’ Novo says in a statement. A search for Fruergaard Jørgensen’s successor is ongoing.

Barrons.com 5 days ago

NVO

LLY
Ozempic boss sacked after falling behind in weight-loss race

The boss of the drugs giant Novo Nordisk has been sacked after falling behind in the global race to develop weight-loss medication.

The Telegraph 5 days ago

NVO

LLY

Performance Overview

Return	LLY.MU	S&P 500 (^GSPC)
YTD	-14.32%	-0.63%
1-Year	-12.70%	+10.13%
3-Year	+141.85%	+49.81%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Eli Lilly and Co (LLY.MU)

Did Eli Lilly Just Say Checkmate to Novo Nordisk?

Wegovy and Zepbound costs capped at $200 in new Evernorth programme

Lilly’s Kisunla marketing for Alzheimer’s authorised in Australia

Lilly's Kisunla (donanemab) receives marketing authorization in Australia for the treatment of early symptomatic Alzheimer's disease

Lilly’s former small molecule head makes the leap to a rising biotech in obesity

Novo Nordisk Places Bet on CEO Shake-Up to Reclaim Edge in Weight Loss Drug Race

Novo Nordisk Shares Dip 3% on Sudden CEO Transition Announcement

Novo Nordisk (NVO) Slides After CEO Departure; Analyst Flags Deeper Strategic Concerns

3 Stocks Estimated To Be Trading Up To 49.2% Below Intrinsic Value

Novo Nordisk’s CEO to step down as weight loss market share plummets

Judge shuts down drugmakers’ 340B rebate plans, for now

Eli Lilly and Co (LLY): Expands Genetic Hearing Loss Pipeline with $1.3B RNA Therapy Partnership

Trump administration not backing down on Big Pharma pressure campaign

Analysis-Novo Nordisk should look to the US for its next CEO, analysts say

From insulin to Ozempic, history of Novo Nordisk's CEOs

Eli Lilly strikes $1.3bn gene therapy deal with Rznomics

Galaxy Digital on the Nasdaq, Novo ousts CEO, Virgin Galactic

Novo Nordisk Sheds 3% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price

Novo Nordisk Boots CEO After Stock Falls 50%. It’s an Unusual Move for the Wegovy Drugmaker.

Ozempic boss sacked after falling behind in weight-loss race

Performance Overview